Stanford Cancer Institute

Head and Neck

**Relapsed or Metastatic**

- **Treatment**
  - Squamous Cell Carcinoma of Head and Neck
  - Ameloblastoma
  - Nasopharyngeal Carcinoma

- **Diagnostic**
  - Squamous Cell Carcinoma of Head and Neck

- **Supportive Care**

- **Correlative**
  - ENT0061
    - Pilot PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
      - PI: Colevas
      - Stanford

- **Key**
  - Pending
  - Open for Enrollment
  - Optional Path
  - Extension Study
  - Immunotherapy

**Network**

**ENT0056**
- Phase III
- Nivolumab in Combo w/ Ipilimumab vs Cetuximab + Cisplatin/Carboplatin + Fluorouracil in SCCHN
- PI: Colevas
- Bristol Myers-Squibb

**ENT0052**
- Phase Ib/II
- IPH2201 And Cetuximab in recurrent or metastatic SCC of head and neck
- PI: Colevas
- Innate Pharm SA

**VAR0132**
- Phase II/II
- Anti-CD27 Antibody (Varilumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Solid Tumors
- PI: Sikic
- Celldex Therapeutics

**ENT0043**
- A Pilot Study of Dabrafenib for Patients with BRAF-Mutated Ameloblastoma
- PI: Colevas
- Stanford

**ENT0050**
- Ph 1
- Panitumumab-IRDye800 Optical Imaging Agent to Detect Head and Neck Cancer During Surgery
- PI: Rosenthal
- Stanford

**ENT0049**
- Ph 1
- Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
- PI: Rosenthal
- Stanford

**ENT0062**
- Phase III
- Gemcitabine & Carboplatin +/- Virusspecific Autologous CTL in Nasopharyngeal Carcinoma
- PI: Colevas
- Pending

**ENT0049**
- Ph 1
- Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
- PI: Rosenthal
- Stanford

**KEY**

- Pending
- Open for Enrollment
- Optional Path
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and fax changes to 725-9204